In vitro enhancement of fluoropyrimidine-induced cytotoxicity by leucovorin in colorectal and gastric carcinoma cell lines but not in non-small-cell lung carcinoma cell lines (original) (raw)

References

  1. Arbuck SG, Douglass HO, Trave F, Milliron S, Baroni M, Nava H, Emrich LJ, Rustum YM (1987) A phase II trial of 5-fluorouracil and high-dose intravenous leucovorin in gastric carcinoma. J Clin Oncol 5: 1150
    Google Scholar
  2. Ardalan B, Glazer R (1981) An update on the biochemistry of 5-fluorouracil. Cancer Treat Rev 8: 157
    Google Scholar
  3. Armstrong RD, Diasio RB (1981) Selective activation of 5′-deoxy-5-fluorouridine by tumor cells as a basis for an improved therapeutic index. Cancer Res 41: 4891
    Google Scholar
  4. Bapat AR, Zarow C, Danenberg PV (1983) Human leukemic cells resistant to 5-fluoro-2′-deoxyuridine contain a thymidylate synthase with lower affinity for nucleotides. J Biol Chem 258: 4130
    Google Scholar
  5. Bellisario RL, Maley GF, Galivan JH, Maley F (1978) Amino acid sequence at the FdUMP binding site of thymidylate synthetase: evidence for an ordered mechanism. Biochemistry 17: 4018
    Google Scholar
  6. Berger SH, Hakala MT (1984) Relationship of dUMP and free FdUMP pools to inhibition of thymidylate synthase by 5-fluorouracil. Mol Pharmacol 265: 303
    Google Scholar
  7. Berger SH, Barbour KW, Berger FG (1988) A naturally occurring variation in thymidylate synthase structure is associated with reduced response to 5-fluoro-2′-deoxyuridine in a human colon tumor cell line. Mol Pharmacol 34: 480
    Google Scholar
  8. Bleyer WA (1989) New vistas for leucovorin in cancer chemotherapy. Cancer 63: 995
    Google Scholar
  9. Bosch L, Harbers E, Heidelberger C (1958) Studies on fluorinated pyrimidines. V. Effects on nucleic acid metabolism in vitro. Cancer Res 18: 335
    Google Scholar
  10. Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248
    Google Scholar
  11. Danenberg PV, Langenbach RJ, Heidelberger C (1974) Structures of reversible and irreversible complexes of thymidylate synthetase and fluoropyrimidine nucleotides. Biochemistry 13: 926
    Google Scholar
  12. Doroshow JH, Leong L, Margolin K, Flanagan B, Goldberg D, Bertrand M, Akman S, Carr B, Odujinrin O, Newman E, Litchfield T (1989) Refractory metastatic breast cancer: salvage therapy with fluorouracil and high-dose continuous infusion leucovorin calcium. J Clin Oncol 7: 439
    Google Scholar
  13. Doroshow JH, Multhauf P, Leong L, Margolin K, Litchfield T, Akman S, Carr B, Bertrand M, Goldberg D, Blayney D, Odujinrin O, Delap R, Shuster J, Newman E (1990) Prospective randomized comparison of fluorouracil versus fluorouracil and high-dose continuous infusion leucovorin calcium for the treatment of advanced measurable colorectal cancer in patients previously unexposed to chemotherapy. J Clin Oncol 8: 491
    Google Scholar
  14. Ehrlichman C, Fine S, Wong A, Elhakeim T (1988) A randomized trial of fluorouracil and folinic acid in patients with metastatic colorectal carcinoma. J Clin Oncol 6: 469
    Google Scholar
  15. Evans RM, Laskin JD, Hakala MT (1980) Assessment of growthlimiting events caused by 5-fluorouracil in mouse cells and in human cells. Cancer Res 40: 4113
    Google Scholar
  16. Evans RM, Laskin JD, Hakala MT (1981) Effects of excess folates and deoxyinosine on the activity and site of action of 5-fluorouracil. Cancer Res 41: 3288
    Google Scholar
  17. Fernandes DJ, Cranford SK (1985) Resistance of CCRF-CEM cloned sublines to 5-fluorodeoxyuridine associated with enhanced phosphatase activities. Biochem Pharmacol 34: 125
    Google Scholar
  18. Heidelberger C (1975) Fluorinated pyrimidines and their nucleosides. In: Sartorelli A, Johns D (eds) Antineop astic and immunosuppressive agents, vol 38, part II. Springer, New York Berlin Heidelberg, p 193
    Google Scholar
  19. Keyomarsi K, Moran RG (1986) Folinic acid augmentation of the effects of fluoropyrimidineson murine and human leukemic cells. Cancer Res 46: 5229
    Google Scholar
  20. Keyomarsi K, Moran RG (1988) Mechanism of the cytotoxic synergism of fluoropyrimidines and folinic acid in mouse leukemic cells. J Biol Chem 263: 14404
    Google Scholar
  21. Laemmli UK (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227: 680
    Google Scholar
  22. Livingston RB, Carter SK (1970) Single agents in cancer chemotherapy. IFI Plenum, New York, p 195
    Google Scholar
  23. Lockshin A, Danenberg PV (1980) Biochemical factors affecting the tightness of 5-fluorodeoxyuridylate binding to human thymidylate synthetase. Biochem Pharmacol 30: 247
    Google Scholar
  24. Martin DS, Stolfi RL, Colofiore JR (1988) Failure of high-dose leucovorin to improve the therapeutic index of the maximally tolerated dose of 5-fluorouracil: a murine study with clinical relevance? J Natl Cancer Inst 80: 496
    Google Scholar
  25. Mini E, Moroson BA, Bertino JR (1987) Cytotoxicity of fluorodeoxyuridine and 5-fluorouracil in human T-lymphoblast leukemia cells: enhancement by leucovorin. Cancer Treat Rep 71: 381
    Google Scholar
  26. Moran RG, Spears CP, Heidelberger C (1979) Biochemical determinants of tumor sensitivity to 5-fluorouracil: ultrasensitive methods for the determination of 5-fluoro-2′-deoxyuridylate, 2′-deoxyuridylate, and thymidylate synthetase. Proc Natl Acad Sci USA 76: 1456
    Google Scholar
  27. Mulkins MA, Heidelberger C (1982) Biochemical characterization of fluoropyrimidine-resistant murine leukemic cells. Cancer Res 42: 965
    Google Scholar
  28. Myer CE, Young RC, Chabner BA (1975) Biochemical determinants of tumor sensitivity to 5-fluorouracil response in vivo. The role of deoxyuridylate pool expansion. J Clin Invest 56: 1231
    Google Scholar
  29. Ohe Y, Nakagawa K, Fujiwara Y, Sasaki Y, Minato K, Bungo M, Niimi S, Horichi N, Fukuda M, Saijo N (1989) In vitro evaluation of the new anticancer agents KT6149, MX-2, SM5887, Menogaril, and Libromycin using cisplatin- or Adriamycin-resistant human cancer cell lines. Cancer Res 49: 4098
    Google Scholar
  30. Ohe Y, Shinkai T, Eguchi K, Sasaki Y, Tamura T, Nakagawa K, Kojima A, Yamada K, Oshita F, Miya T, Saijo N (1990) Negative phase II study of 5-fluorouracil with high-dose leucovorin in non-small cell lung cancer. Jpn J Clin Oncol 20: 364
    Google Scholar
  31. Park J-G, Collins JM, Gazdar AF, Allegra CJ, Steinberg SM, Greene RF, Kramer BS (1988) Enhancement of fluorinated pyrimidine-induced cytotoxicity by leucovorin in human colorectal carcinoma cell lines. J Natl Cancer Inst 80: 1560
    Google Scholar
  32. Park J-G, Kramer BS, Lai S-L, Goldstein LJ, Gazdar AF (1990) Chemosensitivity patterns and expression of human multidrug resistance-associated MDR1 gene by human gastric and colorectal carcinoma cell lines. J Natl Cancer Inst 82: 193
    Google Scholar
  33. Petrelli N, Douglass HO, Herrera L, Russell D, Stablein DM, Brucker HW, Mayer RJ, Schinella R, Green MD, Muggia FM, Megibow A, Greenwals FS, Bukowski RM, Harris J, Levin B, Gaynor E, Loutfi A, Kalser MH, Barkin JSS, Benedetto P, Wolley PV, Nauta R, Weaver DQ, Leichman LP (1989) The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: a prospective randomized phase III trial. J Clin Oncol 7: 1319
    Google Scholar
  34. Poon MA, O'Connell MJ, Moertel CG, Weiand HS, Cullinan SA, Everson LK, Krook JE, Mailliard JA, Laurie JA, Tshetter LK, Wiesenfeld M (1989) Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. J Clin Oncol 7: 1407
    Google Scholar
  35. Radparvar S, Houghton PJ, Houghton JA (1988) Characteristics of thymidylate synthase purified from human colon carcinoma. Arch Biochem Biophys 260: 342
    Google Scholar
  36. Romanini A, Lin JT, Niedzwiecki D, Bunni M, Priest DG, Bertino JR (1991) Role of folylpolyglutamates in biochemical modulation of fluoropyrimidines by leucovorin. Cancer Res 51: 789
    Google Scholar
  37. Santi DV, McHenry CS, Sommer H (1974) Mechanism of interaction of thymidylate synthetase with 5-fluorodeoxyuridylate. Biochemistry 13: 926
    Google Scholar
  38. Sobrero AF, Moir RD, Bertino JR, Handschumacher RE (1985) Defective facilitated diffusion of nucleosides, a primary mechanism of resistance to 5-fluoro-2′-deoxyuridine in the HCT-8 human carcinoma line. Cancer Res 45: 3155
    Google Scholar
  39. Swain SM, Lippman ME, Egan EF, Drake JC, Steinberg SM, Allegra CJ (1989) Fluorouracil and high-dose leucovorin in previously treated patients with metastatic breast cancer. J Clin Oncol 7: 890
    Google Scholar
  40. Tsai C-M, Gazdar AF, Allegra C, Perng R-P, Kramer BS (1990) Enhancement of fluorinated pyrimidine-induced cytotoxicity by leucovorin in human lung cancer cell lines. Int J Cancer 46: 101
    Google Scholar
  41. Ullman B, Melinda L, Martin DW, Santi DV (1978) Cytotoxicity of 5-fluoro-2′-deoxyuridine: requirement for reduced folate cofactors and antagonism by methotrexate. Proc Natl Acad Sci USA 75: 980
    Google Scholar
  42. Vokes EE, Choi KE, Schilsky RL, Moran WJ, Guarnieri CM, Weichselbaum RR, Ranje WR (1988) Cisplatin, fluorouracil, and high-dose leucovorin for recurrent or metastatic head and neck cancer. J Clin Oncol 6: 618
    Google Scholar
  43. Washtien WL (1982) Thymidylate synthetase levels as a factor in 5-fluorodeoxyuridine and methotrexate cytotoxicity in gastrointestinal tumor cells. Mol Pharmacol 21: 723
    Google Scholar
  44. Wendt TG, Hartenstein RC, Wustrow TPU, Lissner J (1989) Cisplatin, fluorouracil with leucovorin calcium enhancement, and synchronous accelerated radiotherapy in the management of locally advanced head and neck cancer: a phase II study. J Clin Oncol 7: 471
    Google Scholar
  45. Zaniboni A, Simoncini E, Marpicati P, Marini G (1988) Phase II study of 5-fluorouracil (5-FU) and high dose folinic acid (HDFA) in hepatocellular carcinoma. Br J Cancer 57: 319
    Google Scholar

Download references